DIAPH1 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with RAGE229 alone or in combination with CML-AGE significantly attenuated DIAPH1–MFN2 interaction by PLA vs. VEH; p < 0.01 and p < 0.001, respectively (Fig. 6d).